Treatment
Sintilimab clinical trials
We’re tracking 172 recruiting studies that include Sintilimab, each written for real people, not researchers, below.
Recruiting studies
- NCT07331883RecruitingPhase 2
Sintilimab and bevacizumab after surgery for ruptured liver cancer
This trial tests whether combining two immune-based drugs (sintilimab and a bevacizumab biosimilar) after surgery can prevent liver cancer from returning in people whose tumor had ruptured. It’s for patients who have had a complete surgical removal of a ruptured hepatocellular carcinoma and are now cancer-free on imaging.
Sanming, FujianAges 18–75 - NCT06773312RecruitingPhase 1
Study of BC001 plus Sintilimab and XELOX for advanced stomach cancer
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06698757RecruitingPhase 2
Testing different cycles of sintilimab before surgery for colorectal cancer
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
Zheng'zhou, HenanAges 18–75 - NCT07309952RecruitingPhase 2
Chemo, immunotherapy and targeted radiation before surgery for advanced lung cancer
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06793956RecruitingPhase 1
Testing sintilimab and linperlisib for NK/T-cell lymphoma
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT05165407RecruitingPhase 2
Study drugs for advanced high-grade neuroendocrine tumors
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT06904014RecruitingPhase 2
Testing a new drug combo before surgery for liver cancer
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Jinan, ShandongAges 18–70 - NCT07194005RecruitingPhase 2
Combination therapy for HER2 1+/2+ advanced stomach cancer
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07186621RecruitingPhase 3
Testing immunotherapy or chemoembolization after liver cancer surgery
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
BeijingAges 18–80 - NCT06742411RecruitingPhase 1/Phase 2
Chemo plus immunotherapy and hyperbaric oxygen for advanced stomach cancer
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
Chengdu, SichuanAges 18–75 - NCT07120698RecruitingPhase 2
MRD-guided sintilimab after surgery for NSCLC
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Guangzhou, GuangdongAges 28–75 - NCT07077512RecruitingPhase 2
CAR-T cells plus immunotherapy for advanced B-cell lymphoma
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
GuangzhouAges 18–70 - NCT07061535RecruitingPhase 2
Sintilimab, tafolecimab and chemo for advanced small cell lung cancer
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
Changsha, HunanAges 18 years+ - NCT07025889RecruitingPhase 1/Phase 2
IBI343 plus sintilimab and chemo for gastric cancer
This trial tests a new combination of IBI343, sintilimab, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. It's for those whose tumors are CLDN18.2-positive and not HER2-positive.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05188859RecruitingPhase 2
Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Taiyuan, ShanxiAges 18 years+ - NCT06931808Enrolling by invitationPhase 4
Fecal transplant with chemo, radiation, and immunotherapy for advanced colon cancer
This study tests a combination of fecal microbiota transplant, chemotherapy, radiation, and immunotherapy (sintilimab) for people with locally advanced rectal cancer. The goal is to see if this approach improves treatment outcomes.
Ningbo, ZhejiangAges 18–75 - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06860490RecruitingPhase 2
Liver cancer trial: HAIC plus immunotherapy and anti-angiogenesis
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT06031285RecruitingPhase 2
Perioperative immunotherapy plus TACE-HAIC for liver cancer with portal vein tumor thrombus
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
Guangzhou, GuangdongAges 18–75 - NCT06761846RecruitingPhase 2
Immunotherapy and chemo after stomach cancer surgery
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04961515RecruitingPhase 2
Orelabrutinib with immunotherapy and temozolomide for CNS lymphoma
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hangzhou, ZhejiangAges 18–75 - NCT06730373RecruitingPhase 2
RC48 plus immunotherapy and chemotherapy for advanced stomach cancer
This study tests a combination of three treatments for advanced stomach cancer that is HER2-positive. The treatments are RC48, an antibody-drug conjugate that targets HER2 on cancer cells, sintilimab, which helps the immune system fight cancer, and S-1, a chemotherapy drug. The goal is to see if the combination is safe and effective as a first-line treatment.
Zhengzhou, HenanAges 18–75
Common questions
- Are there clinical trials studying Sintilimab?
- Yes. Clin2 currently lists 172 recruiting studies that include Sintilimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sintilimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sintilimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sintilimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.